Floatz logo

cd19/bcma car t-cells

Amyloidosis

Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Amyloidosis cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Ascentage Pharma Group Inc.
Phase 3BB
Cyclophosphamide
University of Alabama at Birmingham
Phase 2BB
cc-5013
Ascentage Pharma Group Inc.
Phase 3BB
FILGRASTIM
Memorial Sloan Kettering Cancer Center
Phase 2BB
EVUZAMITIDE
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2BB

View all 29 →

Same molecule, other indications

cd19/bcma car t-cells is also rated in:

POEMS SyndromeDormant
C
Indicative ·
39 / 100
View asset →
Autoimmune Hemolytic AnemiaDormant
C
Indicative ·
39 / 100
View asset →
VasculitisDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →